At Adcentrx, we look beyond a one-size-fits-all platform approach to developing protein conjugates, such as ADCs. Our goal is to develop first-in-class and best-in-class therapies that broaden the therapeutic window in treating cancer and other life-threatening diseases. We do this by optimizing key components of protein conjugate molecular design to solve specific challenges at hand.
Putting this into practice, we created and continue to build the Adcentrx “Toolbox” to intelligently address the issues that arose in previous generations of conjugates. The components of the Toolbox encompass the targeting moiety, the linker, the payload and the conjugation technology.